Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

• Status: Completed
• Trial end date: 2016-05-24
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Opicapone

Criteria

Inclusion Criteria:

• clinical diagnosis with PD

• subjects who are willing to participate in the trial.

• subjects who participated in the BIA 9-1067-302 clinical trial.

Exclusion Criteria:

• subjects who didn't take part at the BIA 9-1067-302 clinical trial.